160 related articles for article (PubMed ID: 8877724)
1. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
MacLean GD; Miles DW; Rubens RD; Reddish MA; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):309-16. PubMed ID: 8877724
[TBL] [Abstract][Full Text] [Related]
2. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Miles D; Papazisis K
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
5. Theratope vaccine (STn-KLH).
Holmberg LA; Sandmaier BM
Expert Opin Biol Ther; 2001 Sep; 1(5):881-91. PubMed ID: 11728222
[TBL] [Abstract][Full Text] [Related]
6. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of the STn-KLH vaccine (Theratope).
Ibrahim NK; Murray JL
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
9. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
10. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: Theratope, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
[TBL] [Abstract][Full Text] [Related]
13. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Holmberg LA; Sandmaier BM
Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
[TBL] [Abstract][Full Text] [Related]
15. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
16. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
18. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
19. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
[TBL] [Abstract][Full Text] [Related]
20. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]